Medpace Holdings (MEDP) EBITDA Margin (2015 - 2026)

Medpace Holdings (MEDP) has 12 years of EBITDA Margin data on file, last reported at 20.76% in Q2 2026.

• Quarterly EBITDA Margin fell 18.0% year-over-year to 20.76% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 20.97% (down 43.0% YoY) and the FY2025 annual result came in at 21.14%, down 5.0% from the prior year.
• EBITDA Margin grew to 20.76% in Q2 2026, from 20.03% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 23.37% in Q4 2024 to a low of 17.01% in Q2 2023.
• A 5-year average of 19.87% and a median of 20.15% in 2022 frame the typical range for EBITDA Margin.
• Annual changes were most pronounced in 2023 — EBITDA Margin sank 304 bps — and 2024, when it soared 585 bps.
• Tracing MEDP's EBITDA Margin over 5 years: stood at 19.39% in 2022, then decreased by 10 bps to 17.52% in 2023, then jumped by 33 bps to 23.37% in 2024, then declined by 7 bps to 21.63% in 2025, then slipped by 4 bps to 20.76% in 2026.
• The last three EBITDA Margin figures came in at 20.76% (Q2 2026), 20.03% (Q1 2026), and 21.63% (Q4 2025), per Business Quant data.